On December 29, 2022, the Consolidated Appropriations Act of 2023 removed the federal requirement for practitioners to submit a Notice of Intent (NOI), or a waiver application, to prescribe medications like buprenorphine, for the treatment of opioid use disorder (OUD). All practitioners who have a current Drug Enforcement Administration (DEA) registration that includes Schedule III authority, may now prescribe buprenorphine for OUD. There are no longer any limits or patient caps on the number of patients a prescriber may treat for OUD with buprenorphine.
On January 17, 2023, the Commonwealth released a memo on Health Care Providers with DEA Controlled Medication Registration which detailed information on the removal of the federal requirement.